Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
-
- Charlene M. Fares
- Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA
-
- Eliezer M. Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
-
- Charles G. Drake
- Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
-
- James P. Allison
- Department of Immunology, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
-
- Siwen Hu-Lieskovan
- Division of Hematology and Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
説明
<jats:p>The emergence of immune checkpoint blockade therapies over the last decade has transformed cancer treatment in a wide range of tumor types. Unprecedented and durable clinical responses in difficult-to-treat cancer histologies have been observed. However, despite these promising long-term responses, the majority of patients fail to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of those who initially respond to treatment eventually experience relapse secondary to acquired resistance. Both primary and acquired resistance are a result of complex and constantly evolving interactions between cancer cells and the immune system. Many mechanisms of resistance have been characterized to date, and more continue to be uncovered. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve clinical outcomes. This review will discuss the landscape of immune checkpoint blockade response data, different resistance mechanisms, and potential therapeutic strategies to overcome resistance.</jats:p>
収録刊行物
-
- American Society of Clinical Oncology Educational Book
-
American Society of Clinical Oncology Educational Book (39), 147-164, 2019-05
American Society of Clinical Oncology (ASCO)
